What is HC Wainwright’s Forecast for ACXP FY2024 Earnings?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Research analysts at HC Wainwright lifted their FY2024 earnings estimates for Acurx Pharmaceuticals in a report issued on Thursday, November 14th. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of ($0.89) for the year, up from their prior forecast of ($0.98). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q4 2024 earnings at ($0.18) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.06) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($3.18) EPS and FY2028 earnings at ($3.35) EPS.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.06. During the same period last year, the business earned ($0.24) EPS.

Acurx Pharmaceuticals Stock Down 1.2 %

NASDAQ:ACXP opened at $1.70 on Monday. Acurx Pharmaceuticals has a 12 month low of $1.52 and a 12 month high of $5.28. The company’s 50-day moving average price is $1.95 and its two-hundred day moving average price is $2.13. The firm has a market cap of $28.71 million, a PE ratio of -1.56 and a beta of -1.73.

Institutional Trading of Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC increased its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 6.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 295,075 shares of the company’s stock after purchasing an additional 16,975 shares during the period. Prospect Financial Services LLC owned 1.86% of Acurx Pharmaceuticals worth $561,000 as of its most recent SEC filing. Institutional investors and hedge funds own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.